Early Antiviral Therapy and Lymphoma Risk in Chronic HCV

08:00 EDT 13 Mar 2019 | Medscape

Chronic HCV infection has been linked to lymphoproliferative disorders. Can early PegIFN/RBV therapy reduce the risk?
Alimentary Pharmacology & Therapeutics

Original Article: Early Antiviral Therapy and Lymphoma Risk in Chronic HCV

More From BioPortfolio on "Early Antiviral Therapy and Lymphoma Risk in Chronic HCV"